Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease | Zendy

Lori Mosca | Zendy; Deborah Grady | Zendy; Elizabeth BarrettConnor | Zendy; Peter Collins | Zendy; Nanette K. Wenger | Zendy; Beth L. Abramson | Zendy; Annlia PaganiniHill | Zendy; Mary Jane Geiger | Zendy; Sherie A. Dowsett | Zendy; Messan G. Amewou-Atisso | Zendy; Marcel Kornitzer | Zendy

Open Access

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

Author(s) -

Lori Mosca,

Deborah Grady,

Elizabeth BarrettConnor,

Peter Collins,

Nanette K. Wenger,

Beth L. Abramson,

Annlia PaganiniHill,

Mary Jane Geiger,

Sherie A. Dowsett,

Messan G. Amewou-Atisso,

Marcel Kornitzer

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.518621

Subject(s) - raloxifene , medicine , stroke (engine) , placebo , incidence (geometry) , selective estrogen receptor modulator , osteoporosis , venous thromboembolism , cardiology , breast cancer , estrogen receptor , cancer , thrombosis , pathology , mechanical engineering , physics , alternative medicine , optics , engineering

Raloxifene, a selective estrogen receptor modulator, reduces risk of invasive breast cancer and osteoporosis, but the effect on risk for stroke and venous thromboembolism in different patient subgroups is not established. The purpose of this analysis was to evaluate the effect of raloxifene on the incidence of all strokes, stroke deaths, and venous thromboembolic events according to participant subgroups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research